Direct oral anticoagulants may be effective and safe for treatment of venous
thromboembolism (VTE) in cancer patients, but they have not been compared with low-
molecular-weight heparin (LMWH), the current recommended treatment for these patients.
The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether
edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients
with cancer. We present the rationale and some design features of the study. One such …

Background The safety and efficacy of edoxaban and dalteparin is unclear for several
cancer groups. Methods We evaluated the occurrence of the primary outcome in large
cancer groups. The primary outcome was the composite of recurrent VTE or major bleeding
over 12 months. Results In patients with gastrointestinal cancer, the primary outcome
occurred in 19.4% patients given edoxaban and in 15.0% given dalteparin (risk difference
[RD], 4.4%; 95%-CI,− 4.1% to 12.8%). The corresponding rates for edoxaban and dalteparin …